<DOC>
	<DOCNO>NCT00739141</DOCNO>
	<brief_summary>The traditional way donor transplant give high dos chemotherapy radiation give stem cell . However , high dos chemotherapy radiation serious side-effects . The doctor think transplant safer likely successful reduce dos chemotherapy radiation . The purpose study find good combination chemotherapy radiation reduce dos follow cord blood transplant treat cancer . The stem cell choose transplant umbilical cord blood . Umbilical cord blood collect healthy newborn baby freeze . One cord blood collection call `` cord blood unit . '' On transplant day , cord blood give catheter like blood transfusion . Transplants do way successful . However , type transplant fairly new . Therefore , important study doctor well understand work . Most blood bone marrow transplant use donor stem cell do part study . When patient study test new way treat think may better old way . We collect information result treatment understand well treatment work . This learn good way treat patient .</brief_summary>
	<brief_title>Conditioning Regimen Transplantation Unrelated Donor Umbilical Cord Blood Patients With Hematologic Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>At least one cycle induction reinduction chemotherapy lymphoma chemotherapy azacitidine decitabine tyrosine kinase inhibitor . Patients aged 1870 year initial referral available suitably match related unrelated donor . Acute myelogenous leukemia ( AML ) : Complete first remission ( CR1 ) high risk relapse : Known prior diagnosis myelodysplasia ( MDS ) myeloproliferative disorder ; Therapy relate AML ; White cell count presentation &gt; 100,000 ; Presence extramedullary leukemia diagnosis ; Any unfavorable sub type FAB WHO classification ; Highrisk cytogenetics ( eg associate MDS , abnormalities 5 , 7 , 8 , Philadelphia chromosome , complex karyotype ) high risk molecular abnormality ; Requirement 2 induction achieve CR1 . Any patient newly diagnose AML intermediate risk cytogenetics . Any patient unable tolerate consolidation chemotherapy would deem appropriate treat physician . Complete second remission ( CR2 ) . Other acute leukemia ambiguous lineage type eg blastic plasmacytoid dendritic cell neoplasm CR1 CR2 Acute lymphoblastic leukemia ( ALL ) : lymphoblastic leukemia ( ALL ) : Complete first remission ( CR1 ) high risk relapse : White cell count presentation &gt; 30,000 Bcell lineage &gt; 100,000 Tcell lineage ; Presence highrisk cytogenetic abnormality ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) MLL rearrangement ( 11q23 ) highrisk molecular abnormality ; Failure achieve complete remission four week induction therapy ; Any patient newly diagnose ALL &gt; = 50 yearsold ; Any patient unable tolerate consolidation and/or maintenance chemotherapy would deem appropriate treat physician . Complete second remission ( CR2 ) . Myelodysplastic Syndrome ( MDS ) : Intermediate1 International Prognostic Scoring System ( IPSS ) score poor risk cytogenetics define IPSS . Intermediate 2 High International Prognostic Scoring System ( IPSS ) score . MDS/ myeloproliferative disorder overlap syndrome . Any score life threaten cytopenia ( ) , include red cell platelet transfusion dependence . Receipt least one cycle cytotoxic chemotherapy , azacitidine decitabine . MDS patient must &lt; = 5 % bone marrow myeloblast ANC &gt; = 0.2 ( growth factor support necessary ) transplant workup . Myeloproliferative Disorder ( MPD ) Lifethreatening cytopenia ( ) , and/or red blood cell platelet transfusion dependence Patients aplasia Patients excess blast less equal 10 % blast bone marrow workup . Chronic myelogenous leukemia ( CML ) patient fail intolerant tyrosine kinase inhibitor patient myeloproliferative disease high risk intent therapy cure . Any NonHodgkins lymphoma ( include chronic lymphocytic leukemia ) Hodgkin 's lymphoma highrisk relapse Eligible patient DLC NHL : relapsed disease follow initial therapy fail mobilize bone marrow involvement therefore suitable autologous transplant OR fail autologous transplant CR salvage chemotherapy . Eligible patient transform indolent NHL/CLL : CR/PR large cell component disease either salvage chemotherapy autologous transplant . Eligible patient mantle cell NHL : highrisk p53 positivity 1st CR/PR initial therapy OR relapse disease follow initial therapy 2nd 3rd CR/PR salvage chemotherapy . Eligible patient indolent B cell NHL ( , limit , follicular , small cell marginal zone NHL ) CLL 2nd subsequent progression ( preallograft cytoreduction necessary CR/PR require ) . Eligible patient HL without progression disease ( POD ) salvage chemotherapy . Timing UCBT : Admission UCBT must within acceptable time period preallograft chemotherapy . Organ Function Performance Status Criteria : Karnofsky score &gt; = 70 % . calculate creatinine clearance &gt; = 60 ml/min bilirubin &lt; = 1.5 mg/dL , ALT &lt; = 3 x upper limit normal unless benign congenital hyperbilirubinemia , pulmonary function ( spirometry correct DLCO ) &gt; = 50 % predict . leave ventricular ejection fraction &gt; = 50 % . albumin &gt; = 3.0 . Graft Criteria : 2 UCB unit select accord current MSKCC unit selection algorithm . High resolution 8 allele HLA typing perform . Unit selection occur base 8 allele HLAmatch CD34+ dose . In addition , unit cryopreserved dose least 1.5 x 10^7 total nucleated cells/recipient body weight ( TNC/kg ) . Units attach segment confirmatory type give preference . Diagnosis : acute leukemia morphologic relapse morphologic persistent disease ( cytogenetic molecular persistence/relapse morphologic CR eligible ) ; MDS CML myeloproliferative disorder &gt; 5 % blast ; Aggressive lymphoma HL POD salvage chemotherapy . Two prior stem cell transplant kind . One prior autologous stem cell transplant within precede 12 month . One prior allogeneic stem cell transplant within precede 24 month . Prior radiation therapy 400cGy TBI . Active uncontrolled infection time transplantation . HIV infection . Seropositivity HTLV1 . Inadequate performance status/ organ function . Pregnancy breast feed . Patient guardian unable give inform consent unable comply treatment protocol include appropriate supportive care , followup , research test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CYCLOPHOSPHAMIDE ( CYTOXAN )</keyword>
	<keyword>CYCLOSPORINE A</keyword>
	<keyword>FLUDARABINE</keyword>
	<keyword>G-CSF</keyword>
	<keyword>MYCOPHENOLATE MOFETIL ( MMF )</keyword>
	<keyword>THI0TEPA</keyword>
	<keyword>UMBILICAL CORD BLOOD ( UCB )</keyword>
	<keyword>08-087</keyword>
</DOC>